Clincosm LogoSign in Get a demo

Effect of Progesterone Levels on 15th Day After Embryo Transfer in Early Miscarriage < 7 WG or Evolving Pregancy Rates

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Recruiting
CT.gov ID
NCT05075174
Collaborator
(none)
540
Enrollment
1
Location
19
Anticipated Duration (Months)
28.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Progesterone level has been studied at days before embryo transfert. But, progesterone blood level has not been studied 15 days after embryo transfert. The aim of this study is to study progesterone level impact at 15 days after embryo transfert on evolving pregnanies or early miscarriages.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    540 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Effect of Progesterone Levels on 15th Day After Embryo Transfer in Early Miscarriage < 7 WG or Evolving Pregancy Rates
    Actual Study Start Date :
    Nov 1, 2020
    Actual Primary Completion Date :
    Sep 1, 2021
    Anticipated Study Completion Date :
    Jun 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. number of blood progesterone [1 day]

      blood progesterone at day 15 after embryo transfert

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 43 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:

    • ART program in Montpellier hospital

    • age >18 years old

    • Blood progesterone level 15 days after embryo transfert

    • Pregnancy development know

    Exclusion criteria:
    • non uterine pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uhmontpellier Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier

    Investigators

    • Study Director: Noémie Ranisavljevic, M.D., Ph.D, University Hospital, Montpellier
    • Principal Investigator: MARIE DUPORT PERCIER, University Hospital, Montpellier

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT05075174
    Other Study ID Numbers:
    • RECHMPL21_0564
    First Posted:
    Oct 12, 2021
    Last Update Posted:
    Oct 12, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Montpellier
    betaHCG +
    pregnancy development know
    progesterone level
    miscarriage
    Additional relevant MeSH terms:
    Abortion, Spontaneous

    Study Results

    No Results Posted as of Oct 12, 2021